Physician profile
Nilesh Kumar
NPI 1053967646
$1,741.61
in general payments reported to CMS, 2019-2025
20 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.73 · 2020: $129 · 2021: $443 · 2022: $530 · 2023: $257 · 2024: $249 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $278.75 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.05 | 2020-2024 | Breztri, Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $259.31 | 2020-2023 | Camzyos |
| Alexion Pharmaceuticals, INC. | $172.96 | 2019-2023 | Ultomiris |
| Abbvie INC. | $126.61 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.90 | 2020-2022 | |
| Gilead Sciences, INC. | $120.38 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.00 | 2022 | |
| Novo Nordisk INC | $43.33 | 2024 | Ozempic, Rybelsus |
| Abiomed | $39.09 | 2023-2024 | Impella |
| Incyte Corporation | $37.21 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $31.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.41 | 2020-2022 | |
| Neurelis, INC. | $28.85 | 2024 | Valtoco |
| Scpharmaceuticals INC. | $23.98 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.06 | 2024 | Xarelto |
| Biogen, INC. | $22.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.48 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.69 | 2021 | |
| Genentech USA, INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.